Kenvue Inc. $KVUE Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. lessened its stake in Kenvue Inc. (NYSE:KVUE) by 17.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 379,123 shares of the company’s stock after selling 81,484 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Kenvue were worth $6,153,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. AlphaCore Capital LLC grew its holdings in Kenvue by 9.9% during the 2nd quarter. AlphaCore Capital LLC now owns 5,287 shares of the company’s stock worth $111,000 after acquiring an additional 476 shares in the last quarter. Empirical Finance LLC lifted its position in shares of Kenvue by 1.8% during the 2nd quarter. Empirical Finance LLC now owns 28,309 shares of the company’s stock worth $593,000 after purchasing an additional 491 shares during the last quarter. J.W. Cole Advisors Inc. lifted its position in shares of Kenvue by 3.8% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 15,488 shares of the company’s stock worth $324,000 after purchasing an additional 574 shares during the last quarter. Spire Wealth Management grew its stake in shares of Kenvue by 13.5% during the second quarter. Spire Wealth Management now owns 4,863 shares of the company’s stock worth $102,000 after purchasing an additional 580 shares in the last quarter. Finally, Versor Investments LP increased its holdings in Kenvue by 2.8% in the third quarter. Versor Investments LP now owns 26,016 shares of the company’s stock valued at $422,000 after buying an additional 716 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Jeffrey C. Smith acquired 3,200,000 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was bought at an average cost of $17.37 per share, with a total value of $55,584,000.00. Following the transaction, the director owned 27,307,632 shares of the company’s stock, valued at $474,333,567.84. The trade was a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 1.68% of the company’s stock.

Kenvue Trading Down 1.1%

Shares of Kenvue stock opened at $18.68 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98. The company has a market capitalization of $35.78 billion, a P/E ratio of 24.25 and a beta of 0.59. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $25.17. The company’s fifty day moving average is $17.51 and its two-hundred day moving average is $17.67.

Kenvue (NYSE:KVUE) last announced its earnings results on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.05. Kenvue had a net margin of 9.72% and a return on equity of 19.86%. The business had revenue of $3.78 billion during the quarter, compared to analysts’ expectations of $3.68 billion. During the same period in the prior year, the company earned $0.26 earnings per share. The business’s revenue was up 3.2% compared to the same quarter last year. Analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th will be given a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a yield of 4.4%. The ex-dividend date of this dividend is Wednesday, February 11th. Kenvue’s dividend payout ratio (DPR) is presently 110.67%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on KVUE. Citigroup lifted their price target on Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday. Edward Jones lowered Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. Barclays upped their price target on Kenvue from $17.00 to $18.00 and gave the company an “equal weight” rating in a report on Monday, November 10th. Canaccord Genuity Group raised their price objective on shares of Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a report on Wednesday. Finally, Johnson Rice restated a “neutral” rating on shares of Kenvue in a research report on Tuesday, October 28th. Four research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $20.08.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.